Introduction
Chemotherapy with various modalities is the standard of care in the management of newly diagnosed and recurrent glioblastoma. Current guidelines recommend intravenous administration of systemic chemotherapy. However, the blood brain barrier (BBB) restricts ionized molecules larger than 180 Da (Daltons) while most chemotherapeutic agents are between 200-1200 Da (TMZ [194 Da]). The doses administered are restricted by their systemic toxicity. Super selective intra-arterial cerebral infusion (SSIACI) can administer a localized regular or higher dose of chemotherapy that circumvents the systemic circulation. This is accompanied by disruption of the BBB (BBBd) which can be achieved in a number of ways (IV mannitol, MRigFUS and bradykinins etc). With super selective catheterization, the drug’s volume of distribution (Vd) is restricted to a targeted area. Additionally, following drug delivery, flow may be arrested to prevent drug washout with blood flow.1

Review of Evidence
Glioblastoma is the most common primary brain malignancy which accounts for almost 50% of malignant brain tumours. The current standard of care in glioblastoma management is maximum safe resection of the enhancing lesion with or without resection of the FLAIR abnormality, followed by 60 Gy of radiation given in 2 fractions daily, 5 days a week for 6 weeks with concomitant temozolamide given 7 days a week at a dose of 75 mg/m². This is followed up with 6 adjuvant cycles consisting of 150-200 mg/m² for 5 days in a 28-day cycle.2

Newton et al., performed the first pilot study for administration of intra-arterial (IA) cisplatin through the internal carotid artery. Twelve patients received a total of 24 infusions with poor response and high rate of complications.3 Madejewicz et al., published a trial of 83 patients with higher grade gliomas (HGGs) in which non-selective IA cisplatin and etoposide were administered prior to or with concomitant radiation therapy in two separate groups. They reported significant improvement in survival in patients receiving IA therapy prior to radiation therapy (RT) and in conclusion noted that this was the best therapy available at the time. They also postulated that concomitant or prior RT reduces the penetration of chemotherapeutic drugs into the tumour bed by damaging the vasculature of the tumour.4

Nimustine is a nitrosurea alkylating agent. Imbesi et al., performed a phase II clinical trial to compare IA vs. IV administration of nimustine in the management of newly diagnosed glioblastoma and found no improvement in progression free survival.5 Kochii et al., reported similar findings.6 Burkhardt et al., performed a single center prospective phase II trial with IA bevacizumab after BBB disruption with mannitol with a reported progression free survival (PFS) of 10 months and an overall survival (OS) of 8.8 months.7

Patel et al., have evaluated the efficacy of IA bevacizumab after disruption of the BBB for treatment of newly diagnosed glioblastoma after surgery. In their study SSIACI was utilized. The results were encouraging with PFS being 11.5 months and OS being 23.1 months. More importantly, PFS at 24 months was 32.5% compared to 26.5% for the Stupp protocol.8 For recurrent glioblastoma, IA bevacizumab with BB8d using mannitol showed significant improvement in PFS of 10 months compared to IV bevacizumab with a PFS between 3.7 and 4.2 months.9 IA administration of temozolomide is not feasible due to its proven brain toxicity in its currently available formulation.10

---

1Northwest School of Medicine, Peshawer, Pakistan;  2,3Aga Khan University Hospital, Karachi, Pakistan  
Correspondence: Muhammad Shahzad Shamim.  
e-mail: shahzad.shamim@aku.edu  
ORCID ID: 0000-0001-8305-8854
Conclusion
SSIACI appears to be a promising avenue with some studies demonstrating benefit over the standard of care. However initial studies also reported a significant complication rate. There are several ongoing studies which are actively recruiting patients and until more results are published, the risk benefit ratio remains inconclusive.

DOI: https://doi.org/10.47391/JPMA.24-55

References